Background: The effect of triptolide (TPL) on cardiac fibroblasts (CFbs) and cardiac fibrosis remain unknown till now.
Introduction
Cardiac fibroblasts (CFbs), the highest cell population in the myocardium, play major roles in maintaining normal cardiac structure and function (Goldsmith et al., 2014) . CFbs are of utmost importance for the pathogenesis of myocardial fibrosis. CFbs promote cardiac repair by controlling the synthesis and degradation of extracellular matrix (Dixon and Cunnington, 2011; Goldsmith et al., 2014) . In the pathological status, some mechanical and chemical stimuli may promote the migration, proliferation and differentiation of CFbs, which may secrete excess amount of collagen fibers. As a result, cardiac fibrosis or myocardial scarring occurs and progresses gradually.
Myocardial fibrosis has already become one of the most difficult stages in the treatment of chronic heart failure (CHF) hence has prognostic relevance. Thus, how to ameliorate myocardial fibrosis is a current research topic in the field of CHF (Heymans et al., 2015) . The mechanisms of CHF are diverse and complex (Yancy et al., 2013) . Among the risk factors, immune-inflammatory activation was reported to be a cornerstone in the development and progression of myocardial fibrosis and CHF. Therefore, anti-inflammatory and immunomodulation therapy has been widely studied around the world and might be a promising strategy for the treatment of CHF in the future Nymo et al., 2014 (Leonard et al., 2002) . However, whether TPL can inhibit the proliferation of CFbs and attenuate myocardial fibrosis in CHF rats are still uncertain. We hypothesized that TPL, as an immunosuppressive agent, could reverse myocardial fibrosis and inhibit CFbs proliferation in CHF rats.
Therefore, a series of experiments in vivo and in vitro were conducted to evaluate the effects of TPL on myocardial fibrosis in rats and on proliferation of CFbs in neonatal rats. In our previous study, we have demonstrated TPL significantly attenuated myocardial fibrosis and improved cardiac function through suppressing several signaling pathways in isoprenaline-induced cardiac remodeling rats . In this study, we assessed the effects of TPL on proliferation and apoptosis of angiotensin II (Ang II)-induced CFbs. This study revealed the effects of TPL on myocardial fibrosis at the cellular level. Methylthiazolyldiphenyl-tetrazolium bromide assay kit (MTT), Annexin V-FITC apoptosis kit and hydroxyproline (HYP) testing kit were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). TRIzol 
Materials and methods

Chemicals
Grouping and interventions
There were four groups set in this study: control (Con), Ang II (Ang), low-dose triptolide (LT) and high-dose triptolide group (HT). Con group was cultured in DMEM/F-12(1:1) only. Ang group was cultured in DMEM/F-12 (1:1) with Ang II (10 -7 mol/L). LT group was cultured in DMEM/F-12(1:1) with Ang II (10 -7 mol/L) and TPL (10 ng/ml). HT group was cultured in DMEM/F -12
(1:1) with Ang II (10 -7 mol/L) and TPL (100 ng/ml). The CFbs in these groups were all incubated under a humidified atmosphere of 5% CO 2 at 37℃ for 48 hours. 
MTT assay
The viabilities of rat CFbs in different groups were calculated to evaluate the proliferation activity in vitro by using the MTT assay. The rat CFbs were harvested and seeded with a rate of 2000 cells per each hole of the 96-well plates at a density of 2×10 4 /mL during the logarithmic growth phase. They were cultured in DMEM/F-12(1:1) with 10% fetal calf serum under a humidified atmosphere of 5% CO 2 at 37℃ for 24 hours. Then, different dosages of drugs were given. The CFbs were further cultured in DMEM/F-12(1:1) with 1% fetal calf serum under the same circumstance.
According to the instruction of MTT assay kit, 50μl of 1×MTT solution was added to each well. The CFbs were incubated in DMEM/F-12(1:1) with 1% fetal calf serum for an additional four hours. Then, 150μl DMSO was used to dissolve the MTT-formazan crystals. The optical density (OD) (λ = 630 nm) was obtained by using a microplate reader.
The corrected ODs were calculated by subtracting the OD of empty well. At last, the viability in each group was calculated according to the following equation: Viability = (Corrected OD of treated group/ Corrected OD of control group) × 100%.
HYP concentration
The rat CFbs were seeded in each well of the 24-well plates at a density of 5×10 5 /mL during the logarithmic growth phase. They were cultured in under a humidified atmosphere of 5% CO 2 at 37℃ for 24 hours. Then, different dosages of drugs were given. Finally, the CFbs were incubated in DMEM/F-12(1:1) with 1% fetal calf serum for an additional 72 hrs. The rat CFbs were harvested and the concentration of HYP was detected according to the assay kit provided by Nanjing Jiancheng Bioengineering Institute (Nanjing, China).
Flow cytometer
Different dosages of drugs were added in each well when the CFbs were in logarithmic growth phase. After an additional 72 hrs incubation, the cells were harvested. Then, Annexinn V-FITC 5μl and PI 5μl were added in the tube for 10 min in a condition away from light. At last, the apoptotic CFbs were identified by flow cytometer and apoptotic rates were calculated by CXP 2.0 software.
Real-time PCR
Total RNA was extracted from CFbs by TRIzol reagent and reverse transcribed to cDNA by the All-in-One TM first strand cDNA synthesis kit. Two microliter cDNA were amplified by quantitative real-time PCR using the All-in-One TM quantitative real-time PCR mix. Beta-actin was used as an internal control gene to normalize the mRNA levels of transforming growth factor-β1 (TGF-β1) and drosophila mothers against decapentaplegic proteins-3 (Smad3). The sequences used in this study were as follows:
5'-GAACCGCTCATTGCCGATAG-3'. Each experiment was performed at least three times.
Statistical analysis
IBM SPSS software Version 20.0 for Windows (SPSS Inc., Chicago, USA) was used for the data analysis. The data were presented as mean ± standard deviation. Normality tests and homogeneity of variance tests were performed. 
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Kruskal-Wallis test was performed if non-normal distribution or heterogeneity of variance was found. A two-tale P<0.05 was considered to indicate a significant difference .
Results
Effects of TPL and Ang on proliferation of rat CFbs
The cultured CFbs in Con group were typical fibroblast morphology which were spindle-shaped or irregular triangle. The CFbs distributed evenly and tightly on the culture flask. In Ang group, the CFbs proliferated significantly, arranged closely and were in the shape of fusiform or square. The numbers of CFbs decreased markedly after the treatment of TPL. There were a few scattered dead cells in the culture flask (Fig.1 ). 
Effect of TPL on viability of rat CFbs
The viability of CFbs in Ang group was significantly higher than that of Con group (P=0.001). Compared to Ang group, the viability of CFbs was markedly reduced in HT group (3.24±1.58 vs. 1.23±0.34, P=0.006). No significant differences of viabilities were found between LT and Ang group (Fig.2) . 
Effect of TPL on HYP concentration in rat CFbs
The HYP concentration in Ang group was significantly higher than that of Con group 
Effect of TPL on apoptosis of rat CFbs
As shown in Fig.4 Therefore, based on the experience of previous studies, some improvements and complements were achieved. In our animal experiment, TPL has shown its antifibrotic effect in isoprenaline-induced CHF and cardiac fibrosis rats . In this in vitro study, the expressions of TGF-β1 and Smad3 mRNA of CFbs were significantly reduced by TPL, indicating that TPL may affect cardiac fibrosis via down-regulating TGF-β1/Smad3 signaling. Besides, we also found that TPL can inhibit the proliferation and reduce the HYP concentration in Ang II-induced CFbs, which were similar to the previous report (Xu et al., 2008) . Furthermore, the pro-apoptic effect of TPL has been reported in lymphoblastic leukemia cells, cardiomyocytes and airway smooth muscle cells Zhou et al., 2015) . In this study, the effect of TPL on CFbs apoptosis was firstly determined. The results indicated that TPL can promote apoptosis of Ang II-induced CFbs in a dose dependent way, which might also play an important role in the antifibrotic effect of TPL in the treatment of myocardial fibrosis. There are some limitations of our study. Firstly, this is a basic research. The results and conclusions cannot be expanded to the clinical aspects relating human beings. TPL cannot be prescribed for the CHF patients yet. Further clinical trials are needed. Secondly, the number of tested groups was rather small. Only two different dosages were set in this study. And there was only one intervention-time point (48 h) set in this study because it's a preliminary experiment. Besides, no inflammatory factors and apoptosis-related proteins were included in this experiment. Therefore, we will test more intervention groups and detect more indexes in the following studies.
In conclusion, TPL can inhibit proliferation, promote apoptosis and reduce the expressions of TGF-β1 and Smad3 mRNA in Ang II-induced CFbs. TPL might be a promising therapeutic drug for myocardial fibrosis. Further studies are needed to explore the potential mechanism and clinical efficiency before it is widely used in CHF patients.
